DRMA
NASDAQDermata Therapeutics Inc.
Price$1.26-0.07 (-4.89%)
02:00 PM07:45 PM
News · 26 weeks51+167%
2025-12-072026-05-31
Mix1890d
- SEC Filings10(56%)
- Market5(28%)
- Other2(11%)
- Insider1(6%)
Latest news
25 items- SECSEC Form EFFECT filed by Dermata Therapeutics Inc.EFFECT - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECSEC Form 424B3 filed by Dermata Therapeutics Inc.424B3 - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECDermata Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECAmendment: SEC Form S-3/A filed by Dermata Therapeutics Inc.S-3/A - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
- SECSEC Form 10-Q filed by Dermata Therapeutics Inc.10-Q - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECDermata Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
- NEWSDermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products -- Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to support skin renewal, in the middle of 2026 -- Raised $2.0 million in net proceeds from it's at-the-market ("ATM") financing facility - SAN DIEGO, CA / ACCESS Newswire / May 13, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW)) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the first quarter ended March 31, 2026."Since announcing our strategic pivot in September 2025, we have m
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
- SECSEC Form DEFA14A filed by Dermata Therapeutics Inc.DEFA14A - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECSEC Form DEF 14A filed by Dermata Therapeutics Inc.DEF 14A - Dermata Therapeutics, Inc. (0001853816) (Filer)
- NEWSDermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has allowed and issued patents in the US, Australia, and Japan covering their BDS with botulinum toxin for the treatment of hyperhidrosis -SAN DIEGO, CA / ACCESS Newswire / April 2, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the Australian Patent Office has accepted its patent application for its topical dermal filler program utilizing its BDS. The patent, entitled "Compositions for the treatment of conditions by dermal fillers," (
- SECSEC Form 10-K filed by Dermata Therapeutics Inc.10-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECDermata Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
- NEWSDermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skincare products under the brand name Tome -- Dermata plans to launch its first DTC product, our Foundational Treatment, a once-weekly mask to support a skin renewal, in the middle of 2026 -- Raised $4.125 million in gross proceeds from a private placement financing in December 2025, including participation from Dermata's Chief Executive Officer, Chief Financial Officer, and a member of the Company's management -SAN DIEGO, CA / ACCESS Newswire / March 26, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW)) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today h
- INSIDERSVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)
- NEWSDermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand -SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a science-driven leader in dermatologic solutions, today announced the appointment of Kyra Peckaitis as Vice President, Marketing. Ms. Peckaitis is a multi-disciplinary brand marketer and will lead Dermata's new brand launch, Tome Skincare. Ms. Peckaitis will oversee the marketing strategy, brand development, and consumer engagement initiatives as Tome gets ready to bring its first commercial products to market in the middle of 2026. Ms. Peckaitis brings years of expe
- NEWSDermata Opens a New Chapter with the Release of Tome Skincare-The oldest new thing in skincare -- Dermata expects to launch its first product in the middle of 2026 -SAN DIEGO, CA / ACCESS Newswire / March 5, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today proudly announces the branding of its latest innovation in skincare: Tome, which aims to introduce "skintech at home". The Company's Tome skincare line will bring intentionally developed skincare that delivers a high level of efficacy by addressing the root causes of skin diseases and conditions. Tome is Studied Skincare™, utilizing timeless ingredients with modern innovations for today's curious skin
- SECDermata Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Dermata Therapeutics Inc.SCHEDULE 13D/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
- SECDermata Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Dermata Therapeutics Inc.SCHEDULE 13D/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
DRMA FAQ
7 questionsWhat does Dermata Therapeutics Inc. do?
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.Where does DRMA stock trade?
Dermata Therapeutics Inc. (DRMA) is listed on NASDAQ.What sector and industry is DRMA in?
Dermata Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Dermata Therapeutics Inc. go public?
Dermata Therapeutics Inc. (DRMA) completed its IPO in 2021.What are analysts saying about DRMA?
Dermata Therapeutics Inc. has had 2 recent analyst actions on file. The most recent action was from Brookline Capital: Buy with a $1400.00 price target on 2021-09-21. Recent price targets range from $900.00 to $1400.00.What companies are similar to DRMA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare DRMA side-by-side with any of them on Quantisnow.How can I track DRMA on Quantisnow?
Quantisnow aggregates Dermata Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DRMA to receive live email and push alerts on every new disclosure.